Written in Blood

Written in Blood

Research from recent issues of Blood

WIB_icon

Predicting Survival Outcomes for Children With Down Syndrome and AML or MDS

Children with Down syndrome (DS) have a higher risk of developing acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML) than those without DS....
WIB_icon

Weighing the Risks and Benefits of Nivolumab in Patients With Hodgkin Lymphoma Undergoing AlloHCT

For patients with Hodgkin lymphoma (HL), allogeneic hematopoietic cell transplantation (alloHCT) can induce long-term disease control; however, relapse is common and rates of 3-year...
WIB_icon

Pembrolizumab Induces Remission in Small Cohort of Patients With Natural Killer/T-Cell Lymphomas

For the 20 to 40 percent of patients with natural killer (NK)/T-cell lymphomas who do not respond to regimens such as SMILE (dexamethasone, methotrexate,...
WIB_icon

Venetoclax Plus Obinutuzumab Effective in Older Adults With CLL and Comorbidities

Patients with chronic lymphocytic leukemia (CLL) are often older at the time of diagnosis (median age = 72 years), and typically receive treatment for...
WIB_icon

Is Ibrutinib Tied to Ventricular Arrhythmias?

Previous studies have indicated that treatment with ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, is associated with a 5 to 15 percent increase in...
WIB_icon

Can Pomalidomide Plus Dexamethasone “Rescue” Patients With Relapsed/ Refractory Amyloid Light-Chain Amyloidosis?

Patients with amyloid light-chain (AL) amyloidosis are often treated upfront with combinations of alkylating agents and bortezomib; when they don’t respond to this regimen...
WIB_icon

Encouraging Trends in Six-Month Mortality in Amyloid Light-Chain Amyloidosis

With recent advances in diagnosis, treatment, and response assessment, clinicians have observed a significant decrease in six-month mortality (p<0.001) among patients with amyloid light-chain...
WIB_icon

Can Podoplanin Explain the Connection Between Brain Tumors and Venous Thromboembolism?

Podoplanin, a sialomucin-like glycoprotein that can induce blood platelet activation, is frequently expressed by primary brain tumors. Its overexpression can contribute to a greater...

Choosing Between Strategies for Managing Fetal or Neonatal Alloimmune Thrombocytopenia

For women diagnosed with fetal and neonatal alloimmune thrombocytopenia (FNAIT), a noninvasive strategy of weekly intravenous immunoglobulin infusion (IVIg) and corticosteroids could help prevent...

Self-Reporting Significantly Overestimates Treatment Adherence in Pediatric Patients With Acute Lymphocytic Leukemia

Maintenance therapy with oral 6-mercaptopurine (6MP) for pediatric patients with acute lymphocytic leukemia (ALL) is crucial for maintaining a durable remission, and poor adherence...
Advertisement

Current Issue

May 2017, Volume 3, Issue 6

This issue discusses the legacy of Agent Orange and hematologic malignancies, a debate over transplant in myelodysplastic syndromes, and more.